Current through Register Vol. 51, No. 19, September 20, 2024
A. In order to enter into a therapy
management contract, a pharmacist:
(1) Shall
be licensed by and in good standing with the Board of Pharmacy;
(2) Shall possess a Doctor of Pharmacy degree
or equivalent training as established in §B of this regulation;
(3) May not have:
(a) A public final order by the Board of
Pharmacy disciplining the pharmacist's license within the 5 years immediately
before the application is submitted; or
(b) Limitations placed on the pharmacist's
license by the Board of Pharmacy in a public order;
(4) Shall possess relevant advanced training
as indicated by one of the following:
(a)
Certification as a specialist related to the disease state specified by the
protocol by:
(i) The Board of Pharmacy
Specialties;
(ii) The American
Society of Consultant Pharmacist's Certified Geriatric Practitioner
certification program; or
(iii)
Another credentialing body approved by the Board of Pharmacy; or
(b) Successful completion of:
(i) A residency accredited by the American
Society of Health-Systems Pharmacists, a body approved by the Board of Pharmacy
or offered by a body accredited by the Accreditation Council for Pharmacy
Education;
(ii) A certificate
program approved by the Board of Pharmacy;
(iii) A National Association of Boards of
Pharmacy credentialing examination; or
(iv) An examination approved by the Board of
Pharmacy;
(5)
Shall have successfully completed:
(a) 1,000
hours of relevant clinical experience; or
(b) 320 hours in a structured experience
program approved by the Board of Pharmacy; and
(6) Shall document training related to the
disease state specified in the protocol.
B. A pharmacist who does not possess a Doctor
of Pharmacy degree shall document that the pharmacist's training has included
the following components:
(1) Designing,
implementing, monitoring, evaluating, and modifying or recommending
modifications in drug therapy to insure effective, safe, and economical patient
care;
(2) Identifying, assessing,
and solving medication-related problems, and providing clinical judgments as to
the continuing effectiveness of individualized therapeutic plans and intended
therapeutic outcomes;
(3)
Conducting appropriate physical assessments, evaluating patient problems, and
ordering and monitoring medications and laboratory tests in accordance with
established standards of practice;
(4) Monitoring patients and patient
populations regarding the purposes, uses, effects, and pharmacoeconomics of
their medications and related therapy;
(5) Providing emergency first care, including
cardiopulmonary resuscitation;
(6)
Using clinical data to optimize therapeutic drug regimens; and
(7) Documenting interventions and evaluating
pharmaceutical care outcomes.
C. The Board of Pharmacy shall determine
whether the pharmacist meets the requirements of §§A and B of this
regulation.
D. An authorized
prescriber who has entered into a prescriber-pharmacist agreement shall submit
to the Boards that regulate the authorized prescriber a copy of:
(1) The prescriber-pharmacist
agreement;
(2) Subsequent
amendments made to the:
(a)
Prescriber-pharmacist agreement; or
(b) Protocols specified in the
prescriber-pharmacist agreement; and
(3) Changes to participants of the:
(a) Prescriber-pharmacist agreement;
or
(b) Protocols specified in the
prescriber-pharmacist agreement.
E. The Boards that regulate the authorized
prescriber shall notify the authorized prescriber of any additional information
needed within 30 days of the receipt of the submitted information.
F. A licensed pharmacist who has entered into
a prescriber-pharmacist agreement shall submit to the Board of Pharmacy a copy
of:
(1) The prescriber-pharmacist
agreement;
(2) Subsequent
amendments made to the:
(a)
Prescriber-pharmacist agreement; or
(b) Protocols specified in the
prescriber-pharmacist agreement; and
(3) Changes to participants of the:
(a) Prescriber-pharmacist agreement;
or
(b) Protocols specified in the
prescriber-pharmacist agreement.
G. The Board of Pharmacy shall determine
whether a pharmacist added under §F of this regulation meets the
requirements of §§A and B of this regulation.
H. The Board of Pharmacy shall notify the
pharmacist of any additional information needed within 30 days of the receipt
of the submitted information.
